Major Adverse Cardiovascular Events (MACE) Archives

FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease

Anemia, Chronic Kidney Disease, Clinical Data, Clinical Trials, End-Stage Kidney Disease, Hemoglobin, Kidney Functioning, Major Adverse Cardiovascular Events (MACE), R&D

FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace FibroGen presented data from two pooled analyses from its roxadustat global […]

Novo Nordisk’s Ozempic Wins Approval for Reducing Cardiovascular Events in Diabetes Patients

Approvals, FDA, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Heart Attacks, Heart Disease, Heart-Related Death, Major Adverse Cardiovascular Events (MACE), New Indications, Stroke, Type 2 Diabetes

Novo Nordisk’s Ozempic (semaglutide) won approval from the U.S. Food and Drug Administration to reduce the risk of major adverse cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.

FDA approves expanded label for Praluent

"Bad" LDL Cholesterol, Approvals, Biotech, Cardiovascular Events, Cholesterol, Drug Pricing, Expanded Label, FDA, FDA/Regulatory, Heart Attacks, Heterozygous Familial Hypercholesterolemia (HeFH), Injectables, Major Adverse Cardiovascular Events (MACE), PCSK9 inhibitors, Statins, Stroke

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.